Last reviewed · How we verify
Swabs containing tea tree oil and chamomile oil
Swabs containing tea tree oil and chamomile oil, developed by Istanbul University - Cerrahpasa, are currently marketed but lack a defined primary indication and revenue data. The key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. The absence of detailed clinical trial results and identified competitors poses a significant risk to assessing the product's market strength and sustainability.
At a glance
| Generic name | Swabs containing tea tree oil and chamomile oil |
|---|---|
| Sponsor | Istanbul University - Cerrahpasa |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: